Combined with the C-map database, it was shown that activation of ANXA5 by Docetaxel, inhibition of EIF5A by Fulvestrant, and inhibition of GNA12 by Tamoxifen increased the risk of AF. This evidence concerns the gene ANXA5 and atrial fibrillation.